Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Acquires 2,562 Shares

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 2,562 shares of the business’s stock in a transaction on Friday, January 16th. The shares were purchased at an average price of $20.00 per share, with a total value of $51,240.00. Following the transaction, the insider owned 1,007,090 shares in the company, valued at $20,141,800. The trade was a 0.26% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Tuesday, January 20th, Group Gp Lp Column III bought 18,052 shares of Surrozen stock. The stock was purchased at an average cost of $19.60 per share, for a total transaction of $353,819.20.
• On Thursday, January 15th, Group Gp Lp Column III purchased 11,893 shares of Surrozen stock. The shares were purchased at an average price of $19.89 per share, for a total transaction of $236,551.77.
• On Wednesday, January 14th, Group Gp Lp Column III acquired 5,523 shares of Surrozen stock. The stock was purchased at an average price of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 13th, Group Gp Lp Column III acquired 12,470 shares of Surrozen stock. The stock was acquired at an average cost of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III bought 15,100 shares of Surrozen stock. The shares were acquired at an average price of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III purchased 30,884 shares of Surrozen stock. The stock was acquired at an average cost of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III purchased 5,266 shares of Surrozen stock. The stock was acquired at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III acquired 315,457 shares of Surrozen stock. The shares were acquired at an average cost of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Stock Performance

NASDAQ:SRZN opened at $17.98 on Wednesday. The stock has a market capitalization of $154.09 million, a price-to-earnings ratio of -0.80 and a beta of 0.58. Surrozen, Inc. has a 1 year low of $5.90 and a 1 year high of $24.94. The stock has a fifty day moving average price of $18.98 and a two-hundred day moving average price of $14.13.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The company had revenue of $0.98 million for the quarter. On average, analysts predict that Surrozen, Inc. will post -8.49 EPS for the current year.

Institutional Investors Weigh In On Surrozen

A number of large investors have recently bought and sold shares of the stock. Stempoint Capital LP raised its position in shares of Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares during the last quarter. Braidwell LP purchased a new stake in Surrozen in the 2nd quarter worth approximately $1,252,000. Millennium Management LLC acquired a new position in Surrozen in the 3rd quarter valued at $1,414,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Surrozen during the 3rd quarter worth $889,000. Finally, Armistice Capital LLC acquired a new stake in shares of Surrozen during the second quarter worth $536,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen News Summary

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Director Tim Kutzkey completed three open‑market buys on Jan 15, Jan 16 and Jan 20 totaling 32,507 shares (~$641k at the reported prices). After the trades he directly owns ~1.02M shares (≈$19.9M value), a roughly 1–1.8% increase in his position; insider buys can be read as a vote of confidence by management. SEC filing — Kutzkey purchases
• Positive Sentiment: Major shareholder Group Gp Lp Column III mirrored the same purchases (Jan 15, 16, 20) for the same share counts and prices, increasing its stake to ~1.02M shares; large‑holder buying reinforces the insider signal and suggests continued institutional support. SEC filing — Group purchases
• Neutral Sentiment: The transactions were disclosed via routine SEC beneficial‑ownership filings; they do not change reported board composition or indicate corporate action (e.g., buyback or financing) beyond increased insider/holder positions. SEC website
• Negative Sentiment: Fundamentals remain a headwind: Surrozen reported a large Q3 earnings miss (EPS -$3.61 vs. -$1.17 expected) and minimal revenue, leaving the company with deep losses — this weak financial profile is the likely driver of downward pressure on the stock despite insider buying. MarketBeat — SRZN profile

Wall Street Analyst Weigh In

SRZN has been the topic of a number of research reports. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.